You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Oral Enzymatic Management of Phenylketonuria

    SBC: ABRI SCIENCE, LLC            Topic: 300

    PhenylketonuriaPKUis a genetic disorder of metabolism characterized by a pathological elevation of phenylalaninePhein the body stemming from a dysfunctional phenylalanine hydroxylase enzymePAHThe resulting high concentrations of Phexcan result in severe intellectual disabilitybehavioral problemsand neurological deficitse gseizuresStrict control of dietary Phe is the primary treatment for PKU curre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy

    SBC: CORD BLOOD PLUS, INC.            Topic: 102

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to move our product forward toward commercialization by improving the quality of life for breast cancer chemotherapy patientsThis will be achieved by the following Specific AimsAimwill optimize differentiation of GMPs and neutrophil lineages in culture in response to G CSFThis will be assessed by flow cytometry to quantify production of ne ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Advance Early Detection of Lupus Nephritis with ClearGold

    SBC: CLEARNANO INC            Topic: 400

    SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. The Daily Progress System- A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment

    SBC: COG ANALYTICS, LLC            Topic: 102

    ABSTRACTSubstance use disordersSUDsincluding opioid use disorderscontinue to be one of the most serious public health issues in the USleading to negative physical and mental health problemsfamily disruptionand premature deathAfrican Americans with drug use histories that are under criminal justice supervision are particularly vulnerable to experiencing the negative consequences associated with SUD ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government